查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016901

旅行疫苗市场：按疫苗类型、剂型、年龄层和最终用户分類的全球市场预测 – 2026-2032 年

Travel Vaccines Market by Vaccine Type, Form, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，旅行疫苗市场价值将达到 141.3 亿美元，到 2026 年将成长至 153.6 亿美元，到 2032 年将达到 259.3 亿美元，复合年增长率为 9.06%。

主要市场统计数据
基准年 2025 141.3亿美元
预计年份：2026年 153.6亿美元
预测年份 2032 259.3亿美元
复合年增长率 (%) 9.06%

本文说明了在旅行模式不断变化和旅行者期望不断提高的情况下，观点旅行疫苗接种仍然至关重要。

随着跨境旅行的恢復和日益多样化，与旅行相关的免疫接种仍然是一项至关重要的公共卫生措施。行前接种疫苗不仅能保护旅客个人，还能透过控制与旅游、商务旅行、移民和人道工作相关的疫苗可预防疾病的传播，进而保护整个目的地社区。旅客在准备出行时会参考不断变化的信息，包括临床指南、目的地特定的入境要求和电子健康证明，这些因素影响着对主要疫苗（例如肝炎、流感和黄热病疫苗）的需求模式。

科学创新、数位技术的应用以及监管的复杂性如何交织，从而重塑全球旅行疫苗接种模式和相关人员的策略？

在疫苗科学的进步、数位医疗的整合以及地缘政治格局对供应链的影响下，旅行疫苗领域正经历着一场变革。包括新型平台和改进的低温运输解决方案在内的技术进步，使得疫苗配方更加持久耐用且适应性更强，从而影响着疫苗接种计划、储存要求和分发方式。同时，用于管理疫苗接种记录、行前风险评估和预约安排的数位医疗工具，正在重塑患者体验，并将网路基地台拓展到传统临床环境之外。

检验进口关税趋势变化对整个旅行免疫网路的采购、低温运输物流和服务交付的连锁反应。

贸易和海关政策的变化会对疫苗及相关物资的物流和供应产生重大影响，而这些物资正是旅游免疫计画的基础。疫苗成分、包装材料或低温运输设备的进口关税或海关税的增加，将促使供应链上的相关人员调整其采购和库存策略，以应对成本压力并维持利润率。製造商和经销商可能会修改与供应商的合同，加快本地化进程，或优先储备关键投入品以减少供应中断。

实用的细分见解，阐明了疫苗类型、给药方法、年龄组和最终用户管道应如何在差异化的临床和商业策略的製定中体现出来。

对市场区隔的深入理解对于优化整个旅行疫苗接种生态系统中的临床指导、分发方式和商业策略至关重要。疫苗类型和成分是关键因素，因为不同的病原体和接种方案——例如甲型和乙型肝炎、流感、脑膜炎球菌病菌感染、狂犬病、伤寒和黄热病——会导致不同的临床紧急程度、旅行前接种时间和储存要求。因此，供应优先顺序和临床医生工作流程必须反映这些临床差异。剂型会影响供应物流和病人偏好。虽然注射疫苗因其有效性和成熟的给药方案而在临床实践中占据主导地位，但口服疫苗可以为某些旅行者群体提供替代方案，并有助于在资源匮乏或偏远地区进行分发。

美洲、欧洲、中东和非洲以及亚太市场旅行疫苗接种的区域趋势和实际影响

地理环境影响疾病流行情况、法律规范和服务提供模式，因此需要针对不同地区采取相应的旅游疫苗接种策略。在美洲，公共卫生系统和私人机构正在携手合作，共同应对南美部分地区黄热病等地方性疾病的风险，并支持与旅行模式重迭的大规模季节性流感疫苗宣传活动。该地区还拥有完善的分发网络，并且数位健康证明的使用率不断提高，这使得在不同次区域间流动的旅客能够更便捷地完成行前筛检和疫苗接种后的记录工作。

主要製造商、经销商和服务供应商如何重组其产品组合、伙伴关係和业务永续营运，以确保旅行者疫苗的供应？

产业相关人员正透过调整产品组合、拓展经销伙伴以及投资生产和物流能力，来满足临床需求并掌握商业性机会。领先的疫苗生产商和产品开发商正在扩展开发平臺，以应对旅游相关病原体的多样性，并提高製剂稳定性和给药便利性。同时，经销商和服务供应商正在加强与专业旅行诊所和药房网路的合作，以简化预约管理、低温运输管理和记录保存流程。

产业领导者应采取切实可行的、高优先顺序的策略步骤，以增强供应链韧性、数位化管道和有针对性的相关人员参与。

旅行疫苗生态系统的领导者应优先考虑一系列切实可行的倡议，以提升临床服务的提供及其商业性可行性。首先，投资供应链冗余和低温运输优化，以降低贸易政策波动和物流中断带来的风险。这包括寻找替代供应商、建立区域填充和包装能力，以及建立透明的库存管理系统。其次，加快在旅客行程中整合数位化流程，透过实施可互通的疫苗接种记录、行前远距远端医疗健康检查以及自动化的预约和疫苗接种提醒，提高疫苗接种率并最大限度地减少错失接种机会。

为了深入了解旅行疫苗接种的实际情况，我们采用了严谨的混合方法研究途径，结合了初步访谈、政策审查和供应链分析。

支持这些发现的研究采用了混合方法，旨在涵盖旅行疫苗接种的临床、营运和政策层面。研究人员对临床医生、旅游医学专家、供应链管理人员和监管专家进行了初步的定性访谈，以直接了解服务提供的挑战和应对策略。此外，研究人员还整合了二手资讯、同侪审查文献、公共卫生机构指南、贸易政策文件和物流报告，以检验影响跨境疫苗流通的临床路径、储存要求和法规环境。

总结整合工作，重点强调在整个旅行疫苗接种生态系统中保持准入、增强韧性和协调相关人员行为的策略重点。

维持可靠且便利的旅客免疫接种服务需要临床、商业和政策部门的协调努力。科学创新、数位转型和不断变化的贸易政策相互作用，为疫苗供应和交付的相关人员带来了机会和挑战。有效应对这一环境需要前瞻性的供应链策略、尊重不同群体差异的有针对性的病人参与，以及反映当地流行病学背景和监管条件的本地化方法。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：旅行疫苗市场：依疫苗类型划分

  • 甲型肝炎
  • B型肝炎
  • 流感
  • 脑膜炎奈瑟菌
  • 狂犬病
  • 伤寒
  • 黄热病

第九章：旅行疫苗市场：依形式划分

  • 注射药物
  • 口服

第十章：旅行疫苗市场：依年龄组别划分

  • 成人版
  • 儿童

第十一章：旅行疫苗市场：依最终用户划分

  • 医院和诊所
  • 网路药房
  • 药局
  • 旅行专科诊所

第十二章 旅行疫苗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：旅行疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 旅行疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国旅行疫苗市场

第十六章：中国旅行疫苗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Bio-Manguinhos
  • Bio-Med（P）Limited
  • Biological E Limited
  • Cadila Pharmaceuticals Limited
  • CSL Limited
  • Dano Vaccines & Biologicals Private Limited
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Incepta Pharmaceuticals Ltd.
  • Indian Immunologicals Ltd.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Perusahaan Umum（Persero）Bio Farma
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-0316851957A3

The Travel Vaccines Market was valued at USD 14.13 billion in 2025 and is projected to grow to USD 15.36 billion in 2026, with a CAGR of 9.06%, reaching USD 25.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.13 billion
Estimated Year [2026] USD 15.36 billion
Forecast Year [2032] USD 25.93 billion
CAGR (%) 9.06%

A concise and authoritative framing of why travel immunization remains essential amid rising mobility patterns and shifting traveler expectations

Travel-related immunization remains a critical public health intervention as cross-border mobility resumes and diversifies. Pre-travel vaccination practices protect both individual travelers and broader host communities by limiting transmission of vaccine-preventable diseases associated with tourism, business travel, migration, and humanitarian deployments. Travelers consult an evolving mix of clinical guidelines, destination-specific entry requirements, and digital health credentials when preparing for trips, and these factors shape demand patterns for core vaccines such as hepatitis, influenza, and yellow fever.

Clinicians and public health authorities continue to adapt vaccination protocols to align with emerging epidemiological data and shifting traveler profiles. The growing prevalence of medical tourism and expatriate assignments has amplified the need for streamlined access to specialized vaccines and reliable post-exposure prophylaxis, particularly for diseases such as rabies and typhoid. Meanwhile, consumer behavior has shifted toward convenience and digital-enabled services, with more travelers seeking pre-travel consultations through telemedicine, rapid access to immunization records, and fulfillment via pharmacies and online channels. These dynamics underscore the importance of integrating clinical guidance, supply chain resilience, and patient-facing technologies to deliver dependable and accessible travel vaccination services.

How scientific innovation, digital enablement, and regulatory complexity are converging to reshape global travel vaccination delivery models and stakeholder strategies

The travel vaccine landscape is undergoing transformative shifts driven by advances in vaccine science, digital health integration, and the geopolitical context that shapes supply chains. Technological progress, including novel platforms and improved cold-chain solutions, is enabling more durable and adaptable vaccine formulations, which in turn affects vaccination schedules, storage requirements, and distribution approaches. Concurrently, digital health tools for vaccination record-keeping, pre-travel risk assessment, and appointment scheduling are reshaping patient journeys and expanding access points beyond traditional clinical settings.

Regulatory alignment across jurisdictions is improving but remains uneven, prompting industry stakeholders to adopt more flexible compliance strategies and to invest in cross-border data interoperability. In parallel, heightened public scrutiny around vaccine safety and efficacy has intensified the need for clear, evidence-based communication from clinicians and manufacturers. As a result, organizations are prioritizing trust-building measures, transparent supply-chain practices, and partnerships with local providers to ensure both preparedness and rapid response capability when outbreak risks change. These structural shifts collectively require a more integrated approach that combines scientific innovation, digital enablement, and resilient logistics to meet traveler needs effectively.

Examining the ripple effects of altered import tariff dynamics on procurement, cold-chain logistics, and service delivery across travel immunization networks

Policy changes in trade and tariff regimes can materially influence the logistics and availability of vaccines and associated supplies that support travel immunization programs. When import duties or tariffs increase on vaccine components, packaging materials, or cold-chain equipment, actors across the supply chain adjust procurement and inventory strategies to absorb cost pressures or to preserve margin. Manufacturers and distributors may re-evaluate supplier contracts, accelerate localization efforts, or prioritize stockpiling of critical inputs to mitigate disruption.

These adjustments cascade to service providers who operate travel clinics, hospital immunization programs, and retail pharmacy channels. Clinics with narrow operating margins may revise service pricing, negotiate different supply terms, or shift sourcing toward domestically produced alternatives where feasible. At the same time, freight and logistics partners must adapt routing and warehousing strategies to maintain temperature-sensitive integrity while controlling costs. From a strategic standpoint, sustained tariff changes prompt stakeholders to strengthen vendor diversification, increase transparency in procurement, and engage proactively with policymakers to clarify exemptions and harmonized standards. In effect, trade policy volatility amplifies the need for contingency planning across clinical, commercial, and regulatory frontiers to maintain reliable access to travel vaccines and related services.

Actionable segmentation insights that clarify how vaccine type, delivery form, age groups, and end-user channels must inform differentiated clinical and commercial strategies

A nuanced understanding of segmentation is essential for tailoring clinical guidance, distribution approaches, and commercial strategies across the travel vaccination ecosystem. Vaccine type composition matters because different pathogens and immunization regimens-such as those for hepatitis A and B, influenza, meningococcal disease, rabies, typhoid, and yellow fever-carry distinct clinical urgency, pre-travel timing, and storage considerations; therefore, supply prioritization and clinician workflows must reflect these clinical differences. Form factors influence delivery logistics and patient preference, as injectable formulations dominate in clinical settings due to efficacy and established administration protocols, while oral vaccines offer alternative pathways for certain traveler groups and can ease outreach in low-resource or remote scenarios.

Age group segmentation creates divergent clinical pathways and communication needs; adult travelers commonly require routine boosters or destination-specific immunizations, whereas pediatric travelers demand age-appropriate dosing, consent pathways, and integration with routine childhood vaccination schedules. End-user segmentation affects distribution and access: hospitals and clinics handle complex clinical cases and specialist immunizations, pharmacies offer convenient walk-in access and replenishment, travel clinics provide tailored pre-travel risk assessment and multi-dose schedules, and online pharmacies extend reach through home delivery and digital record synchronization. By aligning product portfolios, service models, and patient engagement tactics to these segmentation dimensions, stakeholders can enhance coverage, reduce missed opportunities for vaccination, and improve the overall traveler experience.

Regional dynamics and practical implications for travel vaccine delivery across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic context shapes disease prevalence, regulatory frameworks, and service delivery models, requiring region-specific approaches to travel vaccination. In the Americas, public health systems and private providers coordinate to address endemic risks such as yellow fever in parts of South America and to support large-scale seasonal influenza campaigns that intersect with travel patterns. This region also demonstrates advanced distribution networks and a growing adoption of digital health credentials, enabling more seamless pre-travel clearance and post-vaccination documentation for travelers moving between subregions.

Europe, the Middle East, and Africa present a diverse regulatory landscape and a wide range of clinical capacities. Several European countries maintain rigorous pre-travel advisory services and centralized vaccination programs, while parts of Africa face persistent challenges related to cold-chain infrastructure and access to specialized vaccines. The Middle East is an important transit corridor with high passenger throughput, which elevates the importance of vaccination verification and outbreak preparedness. Asia-Pacific is characterized by robust manufacturing capability in some markets, rising demand driven by outbound tourism, and persistent endemic concerns such as typhoid and rabies in specific subregions. The region also shows rapid growth in digital health adoption and private-sector innovation, which supports expanded access through pharmacies and telehealth-enabled travel clinics. Understanding these regional differences enables more effective allocation of clinical resources, targeted public health messaging, and strategic partnerships that reflect local needs and capacities.

How leading manufacturers, distributors, and service providers are reshaping portfolios, partnerships, and operational resilience to secure travel vaccination delivery

Industry participants are responding to both clinical imperatives and commercial opportunities by adapting portfolios, extending distribution partnerships, and investing in manufacturing and logistics capabilities. Leading vaccine producers and product innovators are expanding their development pipelines to address travel-related pathogen diversity and to improve formulation stability and administration convenience. At the same time, distributors and service providers are forging closer collaborations with specialty travel clinics and pharmacy networks to streamline appointment scheduling, cold-chain handling, and record-keeping.

Commercial strategies increasingly emphasize resilience and flexibility: companies are exploring capacity-sharing agreements, regional fill-and-finish operations, and tiered pricing mechanisms to address procurement variability. Strategic alliances with digital platform providers enable integrated pre-travel assessments, automated reminders for multi-dose series, and smoother verification of immunization status at points of care. Additionally, quality assurance and regulatory readiness remain central to company planning, with firms investing in robust pharmacovigilance and in-market support to sustain clinician confidence and to navigate complex approval pathways across jurisdictions.

Practical and prioritized strategic actions that industry leaders should implement to reinforce supply resilience, digital access, and targeted stakeholder collaboration

Leaders in the travel vaccine ecosystem should prioritize a set of practical actions that strengthen clinical service delivery and commercial viability. First, invest in supply chain redundancy and cold-chain optimization to reduce vulnerability to trade policy shocks and logistical disruptions; this includes establishing alternative suppliers, regional fill-and-finish capabilities, and transparent inventory management systems. Second, accelerate digital integration across the traveler journey by deploying interoperable vaccination records, telemedicine pre-travel assessments, and automated appointment and dosing reminders to increase uptake and minimize missed opportunities.

Third, tailor engagement models to segmentation and regional needs by aligning product offerings and distribution channels with vaccine type, form, age group, and end-user characteristics. Fourth, enhance stakeholder collaboration by building strategic partnerships among manufacturers, distributors, travel clinics, and pharmacy networks to enable coordinated response to outbreak risks and to streamline patient access. Fifth, strengthen public communication strategies to address hesitancy through evidence-based messaging, clinician training, and targeted outreach for high-risk traveler cohorts. Finally, embed regulatory and policy engagement in planning to influence tariff and trade discussions, secure exemptions where possible, and support harmonized standards that facilitate cross-border vaccine movement and recognition.

A rigorous mixed-methods research approach combining primary interviews, policy review, and supply-chain analysis to underpin practical travel vaccination insights

The research underpinning these insights employed a mixed-methods approach designed to capture clinical, operational, and policy dimensions of travel immunization. Primary qualitative interviews were conducted with clinicians, travel-medicine specialists, supply-chain managers, and regulatory experts to gather direct observations about service delivery challenges and adaptation strategies. Secondary source synthesis drew on peer-reviewed literature, public health agency guidance, trade policy documents, and logistics reports to validate clinical pathways, storage requirements, and the regulatory context affecting cross-border vaccine movement.

Analytical methods combined thematic analysis of interview transcripts with supply-chain mapping and comparative policy review across the principal regions. Triangulation procedures ensured that reported findings aligned with multiple independent information sources and that conclusions reflected convergent evidence rather than single-source assumptions. The methodology also accounted for limitations: while qualitative depth provided rich operational detail, stakeholder perspectives may vary by market and subpopulation, and rapid policy changes can alter regulatory conditions. To address this, the research incorporated continuous validation checkpoints with clinical advisors and logistics partners to ensure practical relevance and timeliness of insights.

Conclusive synthesis emphasizing strategic priorities for preserving access, building resilience, and aligning stakeholder actions across the travel vaccination ecosystem

Maintaining reliable and accessible travel immunization services requires coordinated action across clinical, commercial, and policy domains. The converging forces of scientific innovation, digital transformation, and evolving trade policy create both opportunities and vulnerabilities for stakeholders who manage vaccine supply and delivery. Effectively navigating this environment demands proactive supply-chain strategies, targeted patient engagement that respects segmentation differences, and regionally tailored approaches that reflect local epidemiology and regulatory conditions.

Organizations that invest in interoperability of vaccination records, strengthen partnerships across distribution channels, and engage constructively with policymakers will be better positioned to sustain access and to respond efficiently when risks change. Importantly, clear communication and clinician-led education remain foundational for maintaining public trust and for ensuring that travelers receive timely, evidence-based protection. By aligning operational tactics with strategic foresight, stakeholders can preserve continuity of care for travelers while advancing resilient and equitable vaccination services.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Travel Vaccines Market, by Vaccine Type

  • 8.1. Hepatitis A
  • 8.2. Hepatitis B
  • 8.3. Influenza
  • 8.4. Meningococcal
  • 8.5. Rabies
  • 8.6. Typhoid
  • 8.7. Yellow Fever

9. Travel Vaccines Market, by Form

  • 9.1. Injectable
  • 9.2. Oral

10. Travel Vaccines Market, by Age Group

  • 10.1. Adult
  • 10.2. Pediatric

11. Travel Vaccines Market, by End User

  • 11.1. Hospitals & Clinics
  • 11.2. Online Pharmacies
  • 11.3. Pharmacies
  • 11.4. Travel Clinics

12. Travel Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Travel Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Travel Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Travel Vaccines Market

16. China Travel Vaccines Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AstraZeneca PLC
  • 17.7. Bavarian Nordic A/S
  • 17.8. Bharat Biotech International Limited
  • 17.9. Bio-Manguinhos
  • 17.10. Bio-Med (P) Limited
  • 17.11. Biological E Limited
  • 17.12. Cadila Pharmaceuticals Limited
  • 17.13. CSL Limited
  • 17.14. Dano Vaccines & Biologicals Private Limited
  • 17.15. Dynavax Technologies Corporation
  • 17.16. Emergent BioSolutions Inc.
  • 17.17. GlaxoSmithKline plc
  • 17.18. Incepta Pharmaceuticals Ltd.
  • 17.19. Indian Immunologicals Ltd.
  • 17.20. Johnson & Johnson Services, Inc
  • 17.21. Merck & Co., Inc.
  • 17.22. Novartis AG
  • 17.23. Perusahaan Umum (Persero) Bio Farma
  • 17.24. Pfizer Inc.
  • 17.25. Sanofi S.A.
  • 17.26. Serum Institute of India Pvt. Ltd.
  • 17.27. Shenzhen Kangtai Biological Products Co., Ltd.
  • 17.28. Takeda Pharmaceutical Company Limited
  • 17.29. Valneva SE
  • 17.30. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GCC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GCC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GCC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 101. GCC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GCC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. G7 TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. G7 TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. G7 TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 116. G7 TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. G7 TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NATO TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NATO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 121. NATO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NATO TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. CHINA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. CHINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)